Latest News

Slowed growth in prescription drug spending driven by HCV drugs


 

National health spending amounted to $3.3 trillion or $10,348/person, a 4.3% increase in 2016, according to the Centers for Medicare & Medicaid Services. This was a slower rate of growth than the 5.8% growth in 2015 because of slower insurance enrollment and declines in spending for services and retail prescription drugs.

The growth in spending on prescription drugs in 2016 declined significantly – 1.3% in 2016 vs. 8.9% in 2015. Strong growth in spending for drugs used to treat hepatitis C contributed to high overall spending growth in 2014 and 2015, which changed in 2016. Prescription drug spending in 2016 grew more slowly partially because spending for drugs used to treat hepatitis C decreased, as fewer patients received treatment and net prices for these drugs declined, the report stated .

"The 2016 rate of prescription drug spending growth is more in line with the lower average annual growth during the period 2010–13 of 1.2 percent—a rate that was driven by the shift to more consumption of generic drugs, which was partly influenced by the loss of patent protection of major brand-name drugs," the authors noted.

Recommended Reading

Study supports routine rapid HCV testing for at-risk youth
MDedge Infectious Disease
New antiviral combination for HCV infection in kidney disease
MDedge Infectious Disease
Targeted strategies better for birth cohort HCV testing
MDedge Infectious Disease
Hep C screening falling short in neonatal abstinence syndrome infants
MDedge Infectious Disease
State regulations for tattoo facilities increased blood donor pools
MDedge Infectious Disease
VIDEO: Project ECHO would cost-effectively expand HCV treatment
MDedge Infectious Disease
Middle-aged hepatocellular carcinoma patients increasingly ineligible for transplant
MDedge Infectious Disease
Eradicating HCV significantly improved liver stiffness in meta-analysis
MDedge Infectious Disease
Denmark reinstates ID NAT screening for blood donations
MDedge Infectious Disease
Model validates use of HCV+ livers for transplant
MDedge Infectious Disease